Future Oncology, Volume 20, Issue 16 (2024)

Browse this journal

Future Oncology, Volume 20, Issue 16 (2024)

See all volumes and issues
Volume 20, 2024 Vol 19, 2023 Vol 18, 2022 Vol 17, 2021 Vol 16, 2020 Vol 15, 2019 Vol 14, 2018 Vol 13, 2017 Vol 12, 2016 Vol 11, 2015 Vol 10, 2014 Vol 9, 2013 Vol 8, 2012 Vol 7, 2011 Vol 6, 2010 Vol 5, 2009 Vol 4, 2008 Vol 3, 2007 Vol 2, 2006 Vol 1, 2005
Download citations Download PDFs Download issue

Future Oncology

Articles

Plain Language Summary of Publication
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussein, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan W Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd & Bruce E Johnson
Pages: 1047-1055
Published online: 15 Feb 2024
AbstractforA plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer | Full Text | PDF (1.7 MB)
  • 1995 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Method
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Dong-Wan Kim, Alison M Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, Michaël Duruisseaux, Stephen V Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew Joe, Shekeab Jauhari, Jim Ford & Koichi Goto
Pages: 1057-1067
Published online: 13 Feb 2024
AbstractforThe phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | Full Text | References | PDF (3 MB) | EPUB
  • 2134 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Method
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors
Changhoon Yoo, Angela Lamarca, Hye Jin Choi, Arndt Vogel, Michael J Pishvaian, Lipika Goyal, Makoto Ueno, Angela Märten, Michael Teufel, Lijiang Geng & Chigusa Morizane
Pages: 1069-1077
Published online: 12 Jan 2024
AbstractforBrightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors | Full Text | References | PDF (1.9 MB) | EPUB
  • 2561 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Charles Dharmani, Oluwatosin Fofah, Eric Wang, Maribel Salas, Margaret Wooddell, Nora Tu, Jenny Tse, Aimee Near & Gabriel Tinoco
Pages: 1079-1097
Published online: 21 Feb 2024
AbstractforReal-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA | Full Text | References | PDF (2.7 MB) | EPUB | Supplemental
  • 716 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Rapid Communication
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
William Wong, Stacey Kowal, Tu My To, Achal Patel, David Veenstra, Louis Garrison & Meng Li
Pages: 1099-1110
Published online: 23 Jan 2024
AbstractforThe value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations | Full Text | References | PDF (2.2 MB) | EPUB | Supplemental
  • 495 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Rapid Communication
Age-related trends in the incidence of metastatic colorectal cancer from 2010 to 2019 in the USA
Zdravko P Vassilev, Helen Guo, Wenlong Lin, Julie Xu, Nasreen Khan & Xiaozhou Fan
Pages: 1111-1121
Published online: 13 Sep 2023
AbstractforAge-related trends in the incidence of metastatic colorectal cancer from 2010 to 2019 in the USA | Full Text | References | PDF (2.1 MB) | EPUB
  • 739 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Review Article
Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis
Mairead Kearney, Liu Zhang, Elizabeth Hubscher, Mihaela Musat, Sharada Harricharan & Thomas Wilke
Pages: 1123-1137
Published online: 01 Aug 2023
AbstractforUndertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis | Full Text | References | PDF (5.9 MB) | EPUB | Supplemental
  • 1113 Views
  • 2 CrossRef citations
  • 0Altmetric
Open Access

Explore articles

Explore the most recently published articles

N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review
Karim Chamie et al.
Plain Language Summary of Publication | Published online: 2 Jul 2024
Open Access
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
Gerald W Prager et al.
Plain Language Summary of Publication | Published online: 2 Jul 2024
Open Access
Plain language summary and patient perspective of the revised STARS study: long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung cancer
Rachel Jenkins et al.
Plain Language Summary of Publication | Published online: 2 Jul 2024
Open Access
OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer
Junsik Park et al.
Method | Published online: 28 Jun 2024
View all latest articles